ENTO
Income statement / Annual
Last year (2024), Entero Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Entero Therapeutics, Inc.'s net income was -$18.06 M.
See Entero Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$29.27 K
|
$106.21 K
|
$537.40 K
|
$571.15 K
|
$976.98 K
|
$798.45 K
|
$754.00 K
|
$734.50 K
|
$0.00
|
| Gross Profit |
$0.00
|
-$29.27 K
|
-$106.21 K
|
-$537.40 K
|
-$571.15 K
|
-$976.98 K
|
-$798.45 K
|
-$754.00 K
|
-$734.50 K
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$903.94
|
$5.03 M
|
$691.26 K
|
$38.32 M
|
$19.14 M
|
$8.68 K
|
$5.77 K
|
$2.40 K
|
$2.50 K
|
$1.40 K
|
| General & Administrative Expenses |
$14.56 K
|
$10.74 M
|
$11.99 M
|
$18.38 M
|
$7.29 M
|
$6.06 K
|
$7.45 K
|
$7.69 K
|
$4.13 K
|
$3.33 K
|
| Selling & Marketing Expenses |
$156.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$14.72 K
|
$10.74 M
|
$11.99 M
|
$18.38 M
|
$7.29 M
|
$6.06 K
|
$7.45 K
|
$7.69 K
|
$4.13 K
|
$3.33 K
|
| Other Expenses |
-$0.00
|
$0.00
|
-$232.74 K
|
$529.10 K
|
$211.43 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$15.62 K
|
$15.77 M
|
$12.68 M
|
$56.70 M
|
$26.43 M
|
$14.74 K
|
$13.43 K
|
$10.22 K
|
$8.65 K
|
$4.34 K
|
| Cost And Expenses |
$15.62 K
|
$15.77 M
|
$12.68 M
|
$56.70 M
|
$26.43 M
|
$14.74 K
|
$13.43 K
|
$10.22 K
|
$8.65 K
|
$4.34 K
|
| Interest Income |
$0.00
|
$2.53 K
|
$8.42 K
|
$1.17 K
|
$484.00
|
$0.00
|
$101.85
|
$875.20
|
$5.94 K
|
$1.59 K
|
| Interest Expense |
$0.00
|
$22.46 K
|
$15.88 K
|
$11.24 K
|
$5.84 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$48.95 K
|
$29.27 K
|
$29.27 K
|
$542.26 K
|
$565.35 K
|
$635.05
|
$798.45
|
$754.00
|
$734.50
|
$733.60
|
| EBITDA |
-$15.61 K |
-$15.74 M |
-$14.51 M |
-$57.99 M |
-$26.26 M |
-$13.77 M |
-$12.63 M |
-$9.47 M |
-$7.92 M |
-$3.61 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$2.25
|
-$24.16 K
|
-$1.95 M
|
-$1.83 M
|
-$6.24 M
|
-$433.94 K
|
-$311.85 K
|
-$1.02 M
|
-$7.97 M
|
-$1.20 M
|
| Income Before Tax |
-$15.62 K
|
-$15.79 M
|
-$14.63 M
|
-$58.54 M
|
-$32.67 M
|
-$15.18 K
|
-$13.53 K
|
-$11.10 K
|
-$14.59 K
|
-$5.93 K
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$0.00
|
$0.00
|
$126.57 K
|
$26.52 M
|
$15.11 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$18.06 M
|
-$15.79 M
|
-$14.63 M
|
-$58.54 M
|
-$32.67 M
|
-$15.18 M
|
-$13.53 M
|
-$11.10 M
|
-$14.59 M
|
-$5.93 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-3.88 |
-46.96 |
-407.37 |
-27544.98 |
-48255.29 |
-28425.72 |
-36815.89 |
-43847.52 |
-94215.17 |
-25480.07 |
| EPS Diluted |
-5.26 |
-46.96 |
-407.37 |
-27544.98 |
-48255.29 |
-28425.72 |
-36815.89 |
-43847.52 |
-94215.17 |
-25480.07 |
| Weighted Average Shares Out |
$4.65 M
|
$336.34 K
|
$35.91 K
|
$2.13 K
|
$677.05
|
$533.94
|
$367.60
|
$253.07
|
$154.88
|
$232.74
|
| Weighted Average Shares Out Diluted |
$3.43 M
|
$336.34 K
|
$35.91 K
|
$2.13 K
|
$677.05
|
$533.94
|
$367.60
|
$253.07
|
$154.88
|
$232.74
|
| Link |
|
|
|
|
|
|
|
|
|
|
